Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
FibroBiologics, Inc. ( (FBLG) ) has provided an update.
FibroBiologics, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., involving convertible promissory notes totaling $15 million issued in December 2024 and June 2025. By July 2025, several conversions of these notes into common stock had occurred, reducing the principal balances of the Second and Third Notes, while the First Note remained fully intact. These transactions were conducted under an exemption from registration as private offerings.
The most recent analyst rating on (FBLG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.
Spark’s Take on FBLG Stock
According to Spark, TipRanks’ AI Analyst, FBLG is a Underperform.
FibroBiologics, Inc. is in a challenging position typical for early-stage biotech firms. The company’s financials indicate ongoing losses and reliance on external financing, which is a major risk factor. Technical indicators suggest slight momentum but also highlight resistance levels due to its price position below key moving averages. The valuation reflects the unprofitable nature of the firm with no dividend to attract income-focused investors. These factors combined result in a low stock score, emphasizing the company’s need for a clear path to revenue generation.
To see Spark’s full report on FBLG stock, click here.
More about FibroBiologics, Inc.
Average Trading Volume: 354,644
Technical Sentiment Signal: Sell
Current Market Cap: $27.43M
Learn more about FBLG stock on TipRanks’ Stock Analysis page.